HomeMarketsSharesTobu Railway Co., Ltd.

Trade Tobu Railway Co., Ltd. - 9001 CFD

Market is not available at the momentMarket information is presented
as of 2026-10-06T02:26:10+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread6.5
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
¥1,000
Overnight funding adjustment
Charges from full value of position
-0.014438 %
(-¥3)

Trade size with leverage ~ ¥20,000

Money from leverage ~ $¥19,000


-0.01444%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
¥1,000
Overnight funding adjustment
Charges from full value of position
-0.007784 %
(-¥2)

Trade size with leverage ~ ¥20,000

Money from leverage ~ $¥19,000


-0.00778%
Overnight funding adjustment time21:00 (UTC)
CurrencyJPY
Min traded quantity1
Margin5.00%
Stock exchangeJapan
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close2748
Open2748
1-Year Change4.81%
Day's Range2746.7 - 2775

Trade Tobu Railway Co., Ltd. - 9001

About Tobu Railway Co Ltd

TOBU RAILWAY CO., LTD. is a Japan-based company mainly engaged in the railway business. The Company operates in five business segments. The Transportation segment is engaged in the provision of railway, bus, taxi services. The Leisure segment is engaged in the travel business, as well as the operation of amusement parks, hotels and restaurants, sky tree business. The Real Estate segment is mainly engaged in the real estate leasing and subdivision sales activities. The Distribution segment is involved in the operation of department stores. The Others segment is engaged in the construction works, electrical works and other businesses.

Financial summary

BRIEF: For the nine months ended 31 December 2021, Tobu Railway Co Ltd revenues increased 2% to Y367.73B. Net income applicable to common stockholders totaled Y12.16B vs. loss of Y21.94B. Revenues reflect Leisure Business segment increase from Y24.98B to Y68.48B, Real Estate Business segment increase of 53% to Y36.41B, Transportation Business segment increase of 9% to Y128.06B.

Equity composition

FY'07 3Q's WAS & DWAS were estimated, WAS=o/s. UP to FY'02 WAS were estimated. 6&12/04&05:WAS=O/S(estimated). FY'94 documents are not avilable. FY'08 Q1&Q3 WAS=O/S, DWAS was estimated. FY'11 Q1 DWAS was estimated in tanshin report. FY'12 Q1 DWAS was estimated.

Latest shares articles

BNP Paribas stock forecast
BNP Paribas stock forecast: Q2 earnings beat estimates
BNP Paribas is a French banking group whose recent developments include a Swift ledger transaction with HSBC for Siemens and continued focus on eurozone interest rates. Explore third-party BNP price targets and technical analysis. Past performance is not a reliable indicator of future results.
14 hours ago
Boeing stock forecast
Boeing stock forecast: FAA investigates Miami freighter crash
Boeing is a US aerospace manufacturer whose shares remain in focus after a 767-300 freighter crash in Miami prompted an FAA investigation. Explore third-party BA price targets and technical analysis. Past performance is not a reliable indicator of future results.
14 hours ago
CaixaBank stock forecast
CaixaBank stock forecast: BPI exits Angola market
CaixaBank is a Spanish bank whose Portuguese unit, Banco BPI, agreed to sell its 33.35% stake in Banco de Fomento de Angola for €388.5m. Explore third-party CABK price targets and technical analysis. Past performance is not a reliable indicator of future results.
15 hours ago
Valneva stock forecast
Valneva stock forecast: EMA validates Lyme vaccine application
Valneva is a French vaccine company listed on Euronext Paris. In August, the EMA validated the marketing-authorisation application for its Lyme disease vaccine candidate with Pfizer. Explore third-party VLA price targets. Past performance is not a reliable indicator of future results.
19 hours ago

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready